» Articles » PMID: 27349407

Dysferlin Function in Skeletal Muscle: Possible Pathological Mechanisms and Therapeutical Targets in Dysferlinopathies

Overview
Journal Exp Neurol
Specialty Neurology
Date 2016 Jun 29
PMID 27349407
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in the dysferlin gene are linked to a group of muscular dystrophies known as dysferlinopathies. These myopathies are characterized by progressive atrophy. Studies in muscle tissue from dysferlinopathy patients or dysferlin-deficient mice point out its importance in membrane repair. However, expression of dysferlin homologous proteins that restore sarcolemma repair function in dysferlinopathy animal models fail to arrest muscle wasting, therefore suggesting that dysferlin plays other critical roles in muscle function. In the present review, we discuss dysferlin functions in the skeletal muscle, as well as pathological mechanisms related to dysferlin mutations. Particular focus is presented related the effect of dysferlin on cell membrane related function, which affect its repair, vesicle trafficking, as well as Ca(2+) homeostasis. Such mechanisms could provide accessible targets for pharmacological therapies.

Citing Articles

Metabolic dysregulation contributes to the development of dysferlinopathy.

Furrer R, Dilbaz S, Steurer S, Santos G, Karrer-Cardel B, Ritz D Life Sci Alliance. 2025; 8(5).

PMID: 40021220 PMC: 11871293. DOI: 10.26508/lsa.202402991.


Antisense oligonucleotide-mediated exon 27 skipping restores dysferlin function in dysferlinopathy patient-derived muscle cells.

Anwar S, Roshmi R, Woo S, Haque U, Arthur Lee J, Duddy W Mol Ther Nucleic Acids. 2025; 36(1):102443.

PMID: 39967852 PMC: 11834094. DOI: 10.1016/j.omtn.2024.102443.


Challenging Diagnosis of a Patient with Two Novel Variants in the Gene.

Kuchina A, Murtazina A, Borovikov A, Subbotin D, Bardakov S, Akhkiamova M Int J Mol Sci. 2024; 25(19).

PMID: 39409170 PMC: 11476505. DOI: 10.3390/ijms251910841.


Pilot investigations into the mechanistic basis for adverse effects of glucocorticoids in dysferlinopathy.

Lloyd E, Crew R, Haynes V, White R, Mark P, Jackaman C Skelet Muscle. 2024; 14(1):19.

PMID: 39123261 PMC: 11312411. DOI: 10.1186/s13395-024-00350-6.


The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments.

Anwar S, Yokota T Biomolecules. 2024; 14(3).

PMID: 38540676 PMC: 10968265. DOI: 10.3390/biom14030256.